Aflibercept (VEGF Trap) MedChemExpress (MCE)

Product Name	Aflibercept
Synonyms	VEGF trap;Aflibercept;VEGF Trap R1R2;Aflibercept iso-osmotic ophthalmic
CAS	862111-32-8
EINECS
Chemical Formula	C4318H6788N1164O1304S32
Molecular Weight
inchi
Package	500 μg;1 mg
Price	Email to quote
Descriptions	Aflibercept (VEGF Trap) Aflibercept (VEGF Trap) MedChemExpress (MCE) HY-108801A 862111-32-8 97.66% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease. Aflibercept (500 μg/mL Descriptions Aflibercept (VEGF Trap) Aflibercept (VEGF Trap) MedChemExpress (MCE) HY-108801A 862111-32-8 97.66% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease. Aflibercept (500 μg/mL 24 h and 7 d) shows no toxicity on RPE cells, neither in MTT-assay nor in trypan blue exclusion assay[1]. Aflibercept (500 μg/mL 24 h) shows a statistically significant effect on wound healing compared with control in the confluent RPE cell layer with three wounds[1]. Aflibercept (500 μg/mL 7 d) displays a significantly diminished phagocytosis of opsonised latex beads compared to untreated control[1]. Aflibercept (1 and 10 μg/mL 10 h) inhibits VEGF signaling by reducing VEGF-regulated processes, such as permeability and angiogenesis[2]. Aflibercept (10 mg/kg 3 h post-middle cerebral artery occlusion (MCAO)) reduces stroke-induced VEGF-A and VEGFR2 expression, and brain edema, and BBB disruption and improves poststroke survival in obese mice[2]. Aflibercept (18.2 mg/kg and 36.4 mg/kg i.v. once) affects BP, ROS and eNOS production in mice[3]. Human \| \| \| \| \| \| \| \| \| \| [1]. Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct 98(10):1448-52. [Content Brief] [2]. Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug 52(8):2637-2648. [Content Brief] [3]. Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep 42(9):1437-1448. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-04-01 14:45:47

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-04-01 14:45:47

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-04-01 14:45:47

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-04-01 14:45:47

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-04-01 14:45:47

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-04-01 14:45:47

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-04-01 14:45:47

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact